Clinical trials: Healthy Japanese
Healthy
Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers
Study to investigate the relative bioavailability and pharmacokinetics of the fixed-dose combination tablets (telmisartan 40 mg/amlodipine 5 mg and telmisartan 80 mg/amlodipine 5 mg) in the fed condition compared with those of…
- Trial name
- NCT02261064
- Testing
- Telmisartan/Amlodipine low dose, Telmisartan/Amlodipine high dose, Japanese meal
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pharmacodynamics Study
Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects
The purpose of this study is to assess the pharmacodynamics (intragastric pH) after repeated oral administration of D961H 10 mg and omeprazole 10 mg in Japanese healthy male subjects who are classified by the genotype of CYP2C19…
- Trial name
- NCT01159145
- Testing
- D961H, Omeprazole
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects
This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy…
- Trial name
- JSAD (NCT00970775)
- Testing
- AZD2423
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1358894 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03875001
- Testing
- Dose group 1 - 50 mg BI 1358894, Dose group 2 - 100 mg BI 1358894, Dose group 3 - 200 mg BI 1358894
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers
This study is a phase 1 study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT03232905
- Testing
- PF-06651600
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
This is a Phase 1, open-label, randomized, parallel design study to evaluate the PK and safety/tolerability of CC 90001 in Japanese and Caucasian healthy adult subjects.
- Trial name
- NCT03958864
- Testing
- CC-90001
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising doses in healthy Asian male volunteers.
- Trial name
- NCT01917916
- Testing
- BI 655064
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pneumococcal Infections
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)
The purpose of this clinical study is to evaluate the safety and immunogenicity of a 4-dose schedule (3-dose primary series followed by a toddler dose) of V114 compared with Pneumococcal 13-valent Conjugate Vaccine (PCV13).
- Trial name
- NCT04384107
- Testing
- V114, PCV13
- Where
- 45 sites in Japan
- Volunteers
- 694 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteer
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
The purpose of this study is to evaluate the bioequivalence of a 100-mg tapentadol (CG5503) dose administered as two 50-mg ER, TRF tablets relative to one 100-mg ER TRF tablet in healthy Japanese male participants.
- Trial name
- NCT01273532
- Testing
- tapentadol (CG5503) ER 100-mg TRF, tapentadol (CG5503) ER 50-mg TRF
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated
The main objective of this trial is to investigate the safety and tolerability of BI 730357 in Japanese healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03793621
- Testing
- BI 730357
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers Type 2 Diabetes
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide.
- Trial name
- NCT04878406
- Testing
- NNC0480-0389, Semaglutide
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Pulmonary Disease, Chronic Obstructive
Study of Danirixin in Japanese Healthy Elderly Male Subjects
Danirixin is a selective chemokine receptor antagonist being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03136380
- Testing
- GSK1325756H
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600…
- Trial name
- NCT02933580
- Testing
- JNJ-56136379
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects
A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects
The objectives of this study are to evaluate the safety and tolerability of a single and multiple oral dose of ASP3325 and to evaluate the effect of administration timing on the pharmacodynamics of ASP3325 orally administered…
- Trial name
- NCT02500953
- Testing
- ASP3325
- Where
- Japan
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Asthma
Japanese Phase 1 Study of Mepolizumab
SB-240563 is a fully humanized monoclonal antibody which is specific for human interleukin-5 (IL-5) and has been under development for severe refractory asthma. This study is the first study in Japanese subjects.
- Trial name
- NCT01471327
- Testing
- SB-240563
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
The purpose of this study is to assess the safety and tolerability of multiple ascending oral doses of BMS-986322 in healthy participants of Japanese descent.
- Trial name
- NCT05546151
- Testing
- BMS-986322
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants.
- Trial name
- NCT02641041
- Testing
- BIIB033
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
A Study of JNJ-40411813 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose and multiple dose administrations of JNJ-40411813 in Japanese healthy adult male participants.
- Trial name
- NCT04677530
- Testing
- JNJ-40411813
- Where
- Japan
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Skin and Connective Tissue Diseases
Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
The purpose of the study is to investigate skin irritation of LEO 80185 gel, gel vehicle and Liquid Paraffin in healthy Japanese male subjects.
- Trial name
- NCT02379793
- Testing
- LEO 80185 gel, vehicle, liquid paraffin
- Where
- Japan
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- LEO Pharma